Renova Therapeutics is working toward a future where patients with chronic diseases will have the benefits that gene and peptide therapies will offer for restoring health. We are working on therapies to transform the treatment of patients suffering from some of the most common and devastating chronic conditions in the world: congestive heart failure and type II diabetes.
Founded in 2009 by pioneers in biopharmaceuticals, Renova Therapeutics is at work creating a portfolio of definitive gene and peptide therapies to transform the lives of people suffering from these chronic diseases. Our investigational gene and peptide therapies are based on carefully validated and proprietary research. Today, we are advancing into phase 3 trials with a novel gene therapy for heart failure.
Accompanying our gene therapy programs, we have accelerated our peptide research and development efforts through acquiring exclusive licenses to the urocortin 2 and urocortin 3 related peptides, further strengthening our resolve and commitment to these patients. Stresscopin, one of the member of the urocortin family, has been shown to be safe and efficacious in dogs with irreversible heart failure and in patients suffering from this syndrome. Building on the successful transition of the stresscopin peptide from the laboratory bench to the patient, we are expanding our efforts around this peptide platform to better meet patient needs. We believe that by making our gene and peptide therapies widely accessible, we can help renew millions of lives and positively impact rising health care costs.